LBA67 Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy

Abstract

At a preplanned interim analysis (median follow-up 6.2 mo) of the double-blind, phase 3 COSMIC-311 trial (NCT03690388), C significantly improved progression-free survival (PFS) versus P (HR 0.22, 96% CI 0.13–0.36; p<0.0001) in 187 pts with previously treated RAIR-DTC (Brose, Lancet Oncol; 2021). Pts must have received lenvatinib (L) or sorafenib (S) and progressed during or after 1–2 prior VEGFR inhibitors. We present final analysis with a longer follow-up of all randomized pts (ITT population) and for prespecified subgroups who received prior L, S, or both.